Modulation of antioxidative response in the therapy of hypertension and other cardiovascular diseases

Neuroendocrinology Letters

Volumn 30, Issue SUPPL.1, 2009, Pages 32-35

  Dovinova, Ima ^a   Gardlik, Roman ^b   Palffy, Roland ^b   Kristek, Frantisek ^a   Cacanyiova, Sona ^a   Vantova, Zuzana ^c   Paulikova, Helena ^c  

^a INSTITUTE OF CHEMISTRY   (Slovakia)

^b Physics and Informatics   (Slovakia)

^c SLOVAK UNIVERSITY OF TECHNOLOGY   (Slovakia)

Author keywords

Antioxidants; Gene therapy; Hypertension; Nitric oxide; Reactive oxygen species

Indexed keywords

ACETYLCYSTEINE; ADENOVIRUS VECTOR; ALPHA TOCOPHEROL; ANTIOXIDANT; APOCYNIN; ASCORBIC ACID; BETA 1 ADRENERGIC RECEPTOR; CATALASE; COMPLEMENTARY DNA; COPPER ZINC SUPEROXIDE DISMUTASE; DIPEPTIDYL CARBOXYPEPTIDASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUTATHIONE PEROXIDASE; HEME OXYGENASE 1; HYDROGEN PEROXIDE; ION CHANNEL; MALONALDEHYDE; MANGANESE SUPEROXIDE DISMUTASE; MATRILYSIN; MELATONIN; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RNA; TEMPOL; TETRAHYDROBIOPTERIN; XANTHINE OXIDASE;

ADRENERGIC SYSTEM; ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; ANTIOXIDANT ACTIVITY; ANTIOXIDANT RESPONSIVE ELEMENT; ARTERIAL PRESSURE; BLOOD VESSEL INJURY; BLOOD VESSEL TONE; CARDIOVASCULAR DISEASE; CELL DEATH; CELL DIFFERENTIATION; CELL GROWTH; DOWN REGULATION; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME REGULATION; ESSENTIAL HYPERTENSION; EXERCISE; GENE CONTROL; GENE EXPRESSION; GENE OVEREXPRESSION; GENE REPRESSION; GENE SILENCING; GENE THERAPY; GENE TRANSFER; GENETIC CODE; HEART INFARCTION; HEART MUSCLE; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; IN VIVO STUDY; KIDNEY FUNCTION; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; REBOUND; REVIEW; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TARGET CELL; VASCULAR SMOOTH MUSCLE; VASODILATATION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

EID: 77349117293     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. Arnold AS, Tang YL, Qian K, Shen L, Valencia V, Phillips MI, et al. (2007). Specific beta1-adrenergic receptor silencing with small interfering RNA lowers high blood pressure and improves cardiac function in myocardial ischemia. J Hypertens. 25: 197-205.
2. Csonka C, Pataki T, Kovacs P, Mudie;ller SL, Schroeter ML, Tosaki A, et al. (2000). Effects of oxidative stress on the expression of antioxidative defense enzymes in spontaneously hypertensive rat hearts. Free Rad Biol Med. 29: 612-619.
3. Dovinova I, Cacanyiova S, Faberova V, Kristek F (2009). The effect of an NO donor, pentaerythrityl tetranitrate, on biochemical, functional, and morphological attributes of cardiovascular system of spontaneously hypertensive rats. Gen Physiol Biophys. 28: 86-93.
4. Grosser N, Schröder H (2004). Therapy with NO donors-antiatherogenic and antioxidant actions. Herz. 29: 116-122. German.
5. He J, Bian Y, Gao F, Li M, Qiu L, Wu W, et al. (2009). RNA interference targeting the ACE gene reduced blood pressure and improved myocardial remodelling in SHRs. Clin Sci (Lond). 116: 249-255.
6. Chan SHH, Tai MH, Li ChY, Chan YH (2006). Reduction in molecular synthesis or enzyme activity of superoxide dismutases and catalase contributes to oxidative stress and neurogenic hypertension in spontaneously hypertensive rats. Free Rad Biol Med. 40: 2028-2039.
7. Chu Y, Iida S, Lund DD, Weiss RM, DiBona GF, Watanabe Y, et al. (2003). Gene transfer of extracellular superoxide dismutase reduces arterial pressure in spontaneously hypertensive rats.Circ Res. 92:461-468.
8. Kojda G, Hambrecht R (2005). Molecular mechanisms of vascular adaptations to exercise. Cardiovasc Res. 67:187-197.
9. Kojsova S, Jendekova L, Zicha J, Kunes J, Andriantsitohaina R, Pechánová O (2006). The effect of different antioxidants on nitric oxide production in hypertensive rats. Physiol Res. 55:S3-16.
10. Kopincova J, Puzserova A, Bernatova I (2008). Chronic low-dose L-NAME treatment effect on cardiovascular system of borderline hypertensive rats. Neuroendocrinol Lett. 29: 784-789.
11. Krskova L, Vrabcova M, Zeman M (2007). Effect of melatonin on exploration and anxiety in normotensive and hypertensive rats with high activity of renin-angiogensin system. Neuroendocrinol Lett. 28: 295-301.
12. Kung LC, Chan SH, Wu KL, Ou CC, Tai MH, Chan JY (2008). Mitochondrial respiratory enzyme complexes in RVLM as cellular targets of nitric oxide and superoxide interaction in the antagonism of antihypertensive action of eNOS transgene. Mol Pharmacol. 74: 1319-32.
13. Leung FP, Yung LM, Laher I; Yao X, Chen ZY, Huang Y (2008). Exercise, vascular wall and cardiovascular diseases. Sports Medicine 38: 1009-1024.
14. Li Q, Bolli R, Qui Y, Tang XL, Yiru G, French BA (2001). Gene therapy with extracellular superoxide dismutase protects conscious rabbits against myocardial infarction. Circulation. 103: 1893-1898.
15. Miloradovic Z, Jovovic D, Mihailovic N, Milanovic JG, Milanovic S (2008). Effect of long-term losartan and L-arginine treatment on haemodynamics and SOD activity in SHR. Can J Physiol Pharmacol. 86: 210-214.
16. Modlinger P, Chabrashvili T, Gill PS, Mendonca M, Harrison DG, Griendling KK, et al. (2006). RNA silencing in vivo reveals role of p22phox in rat angiotensin slow pressor response. Hypertension. 47: 238-44.
17. Palffy R, Gardlik R, Hodosy J, Behuliak M, Resko P, Radvansky J, Celec P (2006). Bacteria in gene therapy: bactofection versus alternative gene therapy. Gene Therapy 13: 101-105.
18. Paravicini TM, Touyz RM (2006). Redox signaling in hypertension. Cardiovasc Res. 71: 247-258.
19. Pechanová O, Jendekova L, Vrankova S (2009). Effect of chronic apocynin treatment on nitric oxide and reactive oxygen species production in borderline and spontaneous hypertension. Pharmacol Rep. 61: 116-122.
20. Rodrigo R, Prat H, Passalacqua W, Araya J, Bachler JP (2008). Decrease in oxidative stress through supplementation of vitamins C and E is associated with a reduction in blood pressure in patients with essential hypertension. Clin Sci (Lond). 114: 625-634.
21. Torok J (2008). Participation of Nitric Oxide in Different Models of Experimental Hypertension. Physiol Res. 57: 813-825.
22. Umemoto S, Tanaka M, Kawahara S, Kubo M, Umeji K., Hashimoto R, et al. (2004). Calcium Antagonist Reduces Oxidative Stress By Upregulating Cu/Zn Superoxide Dismutase in Stroke-Prone SHR. Hypertens Res. 27: 877-885.
23. Wang X, Chow FL, Oka T, Hao L, Lopez-Campistrous A, Kelly S, et al. (2009). Matrix metalloproteinase-7 and ADAM-12 define a signaling axis in agonist-induced hypertension and cardiac hypertrophy. Circulation. 119: 2480-2489.
24. Wilcox CS, Pearlman A (2008). Chemistry and antihypertensive effects of tempol and other nitroxides. Pharmacol Rev. 60: 418-469.